Answers are grounded in this paper and cite their sources.
The Markov model predicted that IMPT with DIBH was only cost-effective for selected left-sided breast cancer patients where IMRT resulted in a significantly greater dose to normal tissue. The presented model may serve as a means of evaluating the cost-effectiveness of IMPT on an individual patient basis.
No takes yet. Share an insight, caveat, or question.
Austin et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: